Pediatric acute myeloid leukemias treatment: current scientific view

Abstract

The results of treatment of acute myeloid leukemias (AML) in children remain unsatisfactory. Modern therapeutic programs with hematopoietic stem cell transplantation allow us to get 5-year overall survival rate of 65 % in primary patients. For patients with relapses or refractory AML, 5-year overall survival is about 35 %.This article presents the possibilities of chemotherapy and hematopoietic stem cell transplantation in the treatment of AML. The possibilities of epigenetic, immune, and cellular therapy are presented for pediatric AML. Special attention is paid to targeted drugs that only beginning to be used in the complex therapy of AML.

Keywords

• acute myeloid leukemia
• treatment
• children